Malignant neoplasm of pancreas
|
0.600 |
Biomarker
|
disease |
BEFREE |
Importantly, KRAS was proved to mediate LINC01420-facilitated PC cell proliferation.
|
31562613 |
2020 |
Malignant neoplasm of pancreas
|
0.600 |
Biomarker
|
disease |
BEFREE |
Mu-KRAS attenuates Hippo signaling pathway through PKCι to sustain the growth of pancreatic cancer.
|
31230347 |
2020 |
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Importantly, FGTI-2734 inhibited the growth of xenografts derived from four patients with pancreatic cancer with mutant KRAS (2 G12D and 2 G12V) tumors.
|
31227505 |
2019 |
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
These findings also showed that gene signatures related to KRAS dependency might be prospectively used to inform on decitabine sensitivity in a selected subset of patients with KRAS-mutated pancreatic cancer.
|
31492820 |
2019 |
Malignant neoplasm of pancreas
|
0.600 |
Biomarker
|
disease |
BEFREE |
Western blot analysis revealed that LY-1816 markedly suppressed the Src signaling, and downregulated the expression of FOSL1; FOSL1 is an oncogene vulnerability in KRAS-driven pancreatic cancer.
|
30618127 |
2019 |
Malignant neoplasm of pancreas
|
0.600 |
Biomarker
|
disease |
BEFREE |
Overexpression of DCLK1-AL Increases Tumor Cell Invasion, Drug Resistance, and KRAS Activation and Can Be Targeted to Inhibit Tumorigenesis in Pancreatic Cancer.
|
31467540 |
2019 |
Malignant neoplasm of pancreas
|
0.600 |
Biomarker
|
disease |
BEFREE |
Initially demonstrated in oncogenic KRAS-driven models of pancreatic cancer, macropinocytosis triggers the internalization of extracellular proteins via discrete endocytic vesicles called macropinosomes.
|
30967003 |
2019 |
Malignant neoplasm of pancreas
|
0.600 |
Biomarker
|
disease |
BEFREE |
Among the mutations of N-Ras, H-Ras, and K-Ras, the mutant K-Ras is the most prevalent target for the development of Lungs, colon, and pancreatic cancers.
|
31838977 |
2019 |
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Extensive analysis was performed in terms of cfDNA fragments to explore the reasons for higher detection rate of KRAS mutations in the circulation of pancreatic cancers.
|
30857943 |
2019 |
Malignant neoplasm of pancreas
|
0.600 |
Biomarker
|
disease |
BEFREE |
Oncogenic KRAS Induces NIX-Mediated Mitophagy to Promote Pancreatic Cancer.
|
31263025 |
2019 |
Malignant neoplasm of pancreas
|
0.600 |
Biomarker
|
disease |
BEFREE |
Hence, simultaneously targeting both the TGF-β and KRAS pathways might dismantle the obstacles of pancreatic cancer therapy.
|
31033217 |
2019 |
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Hyperinsulinemia is a risk factor for pancreatic cancer, but the function of insulin in carcinogenesis is unclear, so this study aimed to elucidate the carcinogenic effects of insulin and the synergistic effect with the KRAS mutation in the early stage of pancreatic cancer.
|
30838710 |
2019 |
Malignant neoplasm of pancreas
|
0.600 |
Biomarker
|
disease |
BEFREE |
The receptor for advanced glycation end products (RAGE) has recently emerged as a chemotherapeutic target in KRAS driven pancreatic cancers both for treatment and in chemoprevention.
|
29998364 |
2019 |
Malignant neoplasm of pancreas
|
0.600 |
Biomarker
|
disease |
BEFREE |
The KRAS gene is the most frequently mutated gene in pancreatic cancer, and no successful anti-Ras therapy has been developed.
|
31268978 |
2019 |
Malignant neoplasm of pancreas
|
0.600 |
Biomarker
|
disease |
BEFREE |
The same missense variants between the initial tumor and remnant PC were discovered only in KRAS of one patient, and in HRAS of one patient.
|
30515563 |
2019 |
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Importantly, T-UPSM demonstrated superior safety and antitumor efficacy over triptolide and T-NPSM in KRAS mutant pancreatic cancer mouse models.
|
30912923 |
2019 |
Malignant neoplasm of pancreas
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
KRAS pathway expression changes in pancreatic cancer models by conventional and experimental taxanes.
|
31375828 |
2019 |
Malignant neoplasm of pancreas
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our data suggest a crucial role of LIF in KRAS-driven pancreatic cancer and that blockade of LIF by neutralizing antibodies represents an attractive approach to improving therapeutic outcomes.
|
31296870 |
2019 |
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
KRAS G12D point mutation plays an important role in the incidence of non-small-cell lung cancer (NSCLC) as well as colorectal cancer, pancreatic cancer and breast cancer.
|
30876538 |
2019 |
Malignant neoplasm of pancreas
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our data indicates that targeting the MEK/ERK-FAM83A feed-forward loop opens up additional avenues for clinical therapy that bypass targeting of oncogenic KRAS in aggressive pancreatic cancers.
|
31527715 |
2019 |
Malignant neoplasm of pancreas
|
0.600 |
Biomarker
|
disease |
BEFREE |
We identified several cancer-related SAAVs including KRAS, which is an important oncoprotein in pancreatic cancer.
|
30404448 |
2019 |
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
KRAS is the most commonly mutated oncogene in human cancer, with particularly high mutation frequencies in pancreatic cancers, colorectal cancers, and lung cancers [Ostrem, J. M., and Shokat, K. M. (2016) Nat.Rev.Drug Discovery 15, 771-785].
|
31042025 |
2019 |
Malignant neoplasm of pancreas
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The aforementioned results indicate that KIS37 administration is a novel therapeutic strategy for targeting PDK4 in KRAS-activated intractable human pancreatic cancer.
|
31106493 |
2019 |
Malignant neoplasm of pancreas
|
0.600 |
Biomarker
|
disease |
BEFREE |
KRAS-enhanced macropinocytosis and reduced FcRn-mediated recycling sensitize pancreatic cancer to albumin-conjugated drugs.
|
30653981 |
2019 |
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancer.
|
31406261 |
2019 |